*Annex III*

PERFORMANCE MATRIX

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Criteria and sub-criteria** | **Scoring**  10=high-performing; 0=non-performing; 1=low-performing; N/A=do not know  /not applicable.  OR pass/fail | **Option 0** | **Option 1** | **Option 2** | | **Option 3** | | **Option 4** | **Option 5** | **Option 6** |
| **Status Quo** | **DSI**  **treated as GR** | **Country MAT** | **Globa l MAT** | **Payment for access to DSI** | **Other contribu tions** | **Enhanced TSC and CB** | **No benefit sharing from DSI** | **1% levy on retail sales of GR** |
| **A. Effective in achieving policy goals** |  |  |  |  |  |  |  |  |  |  |
| 1. Potential to deliver predictable monetary benefits |  |  |  |  |  |  |  |  |  |  |
| 2. Potential to deliver predictable non-monetary benefits |  |  |  |  |  |  |  |  |  |  |
| 3. Access to public databases remains open |  |  |  |  |  |  |  |  |  |  |
| 4. Does not hinder research and innovation |  |  |  |  |  |  |  |  |  |  |
| 5. Potential to contribute to the conservation and sustainable use of biodiversity |  |  |  |  |  |  |  |  |  |  |
| **B. Efficient and feasible to implement** |  |  |  |  |  |  |  |  |  |  |
| 6. Technically feasible |  |  |  |  |  |  |  |  |  |  |
| 7. Legally feasible |  |  |  |  |  |  |  |  |  |  |
| 8. Legally clear and certain to implement |  |  |  |  |  |  |  |  |  |  |
| 9. Administratively simple |  |  |  |  |  |  |  |  |  |  |
| 10. Implementable in an efficient and timely manner |  |  |  |  |  |  |  |  |  |  |
| 11. Enables distinction between commercial and non-commercial use of digital sequence information on genetic resources |  |  |  |  |  |  |  |  |  |  |

CBD/WG2020/3/4/Add.1

Page 13

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Criteria and sub-criteria** | **Scoring**  10=high-performing; 0=non-performing; 1=low-performing; N/A=do not know  /not applicable.  OR pass/fail | **Option 0** | **Option 1** | **Option 2** | | **Option 3** | | **Option 4** | **Option 5** | **Option 6** |
| **Status Quo** | **DSI**  **treated as GR** | **Country MAT** | **Globa l MAT** | **Payment for access to DSI** | **Other contribu tions** | **Enhanced TSC and CB** | **No benefit sharing from DSI** | **1% levy on retail sales of GR** |
| 12. Cost of set-up and implementation |  |  |  |  |  |  |  |  |  |  |
| **C. Enables good governance** |  |  |  |  |  |  |  |  |  |  |
| 13. Easy to understand by providers and users |  |  |  |  |  |  |  |  |  |  |
| 14. Easily enforceable by providers |  |  |  |  |  |  |  |  |  |  |
| 15. Ease of compliance for users |  |  |  |  |  |  |  |  |  |  |
| 16. Does result in jurisdiction shopping |  |  |  |  |  |  |  |  |  |  |
| 17. Facilitates the sharing of benefits with indigenous peoples and local communities |  |  |  |  |  |  |  |  |  |  |
| **D. Coherent and adaptable** |  |  |  |  |  |  |  |  |  |  |
| 18. Coherence with other forums considering digital sequence information on genetic resources |  |  |  |  |  |  |  |  |  |  |
| 19. Agile and adaptable to future technological and scientific development |  |  |  |  |  |  |  |  |  |  |